Prostaglandins, Leukotrienes, and Essential Fatty Acids 2001: Vol 64-65 Index

11 Pages·2001·2.8 MB·English

Prostaglandins, Leukotrienes and Essential Fatty Acids (2001) 65(5&6), 307-311
© 2001 Harcourt Publishers Ltd
Subject Index Volume 64&65
L A | Bosentan, improvement of respiratory function in endotoxic shock,
65.103
Bradykinin, effect on prostaglandin production in rat vas deferens,
Acetaldehyde-induced bronchoconstriction in asthmatics, effect of
pranlukast hydrate, 65.41 65.9
Adipogenesis markers, expression in murine stromal cell line, 65.216 Breastfeeding: association of breastfeeding duration, milk fat compo-
Aging sition and developmental indices at one year, 64.105
cognitive deficits, brain and hippocampus fatty acid composition Bronchoconstriction, acetaldehyde-induced, effect of pranlukast
and, 64.189 hydrate, 65.41
paraoxonase and platelet-activating factor acetylhydrolase activ-
ities and, 65.241 c
Airway contractility, effect of dietary n-3 and n-6 polyunsaturated
oils, 64.281 Calcium, involvement in angiotensin II-induced PGF>, release, 65.73
Alloxan-induced cytotoxicity, protective action of arachidonic acid, Calcium ATPase activity, effect of essential fatty acid supplementa-
64.37
tion, 64.147
Angiotensin II, stimulation of PGF2, release via L-type calcium Cancer
channels, 65.73 15-lipoxygenase-1 activity and localization in colorectal carcinoma
Anti-oxidants, vegetarians and non-vegetarians, 64.53
Caco-2 cells, 64.217
Antidepressants, cancer prevention and treatment, 65.233 antidepressants and eicosanoids and: review, 65.233
Apoptosis, role of dietary polyunsaturated fatty acids, 64.151 pancreatic, influence of vitamins A, C and E on lipid peroxidation,
Arachidonic acid (AA)
65.165
effect of AA-rich oil on lipids and arachidonate metabolites in peroxisome proliferator-activated receptor-; expression in malig-
ethanol-treated rats, 64.273 nant and normal cell lines, 241
effects of fatty acyl CoA esters on prostaglandin and arachidonoyl- prostaglandin E2 concentrations in naturally occuring canine
CoA formed from AA in kidney medulla, 64.61 cancer, 64.1
protective action against alloxan-induced cytotoxicity and diabetes role of dietary polyunsaturated fatty acids in preneoplastic
mellitus, 64.37 urothelial proliferation, 64.151
stimulated release by agonists of peroxisome proliferator-activated uptake and metabolic conversion of fatty acids in Hep2 larynx
receptor and retinoic acid receptors, 65.229
tumor cells, 65.295
stimulated release from rat liver cells by celecoxib and indometha-
Celecoxib, and release of arachidonic acid from rat liver cells, 65.31
cin, 65.31 Cells
tyrosine kinase-phosphorylated protein in arachidonic acid-treated
Hep2, uptake and metabolic conversion of fatty acids, 65.295
cells, 65.173 stromal, expression of adipogenesis markers, 65.216
Arachidony] trifluoromethyl ketone induction of lipid body forma- Cognitive deficits, aged-relative, brain and hippocampus fatty acid
tion in leukocytes, 64.227 composition and, 64.189
Arterial disease, peripheral occlusive, effects of intravenous oxygen Colorectal carcinoma, 15-lipoxygenase-1 activity and localization in
on prostacyclin and thromboxane formation, 65.211 Caco-2 cells, 64.217
Arthritis
Corticosteroids, effects in glomerular disorders, 65.197
adjuvant induced, role of novel derivative pentacyclic triterpene Cyclooxygenase (COX), in streptozotocin-pancreatic damage, 64.311
and «3 fatty acid (Lupeol-EPA), 64.81 Cyclooxygenase-2 (COX-2), platelets, 64.299
see also Rheumatoid arthritis Cyclooxygenase-2 selective inhibitors, evaluation on purifed ovine
Aspirin: effect on eicosanoids of low-dose aspirin combined with fish
enzymes and human whole blood, 64.211
oil, 64.291 Cyclopsorine A-induced hypertension, nitric oxide in, role of
Atherosclerosis
f-adrenoreceptor antagonist and thromboxane Az, 65.259
6-0x0-PGF;,, and 8-epi-PGF>, in arterial wall layers, 64.167 Cyclosporine A nephrotoxicity, preventive role of prostanoids and
protective effect of plant sterols, 64.323
endothelins, 64.231
Autism: plasma fatty acid levels in autistic children, 65.1 Cysteinyl leukotriene antagonist, effect on acetaldehyde-induced
bronchoconstriction in asthmatics, 65.41
B Cytotoxicity, alloxan-induced, protective action of arachidonic acid,
64.37
Beraprost, effects compared with PGE, nitroglycerin and nifedipine,
| D J
64.197
Beta-adrenoceptor antagonist, cyclopsorine A-induced hypertension,
65.259 15-Deoxy4S12,14s-prostaglandin Jz, effect on adipogenesis in
BM-573 activity on platelet function and isolated smooth muscles, stromal cell lines, 65.215
65.67 Diabetes mellitus
Bone modulation of PGE2 generation in diabetic embryo, 64.127
immunohistochemical localization of prostacyclin receptor (IP), protective action of arachidonic acid, 64.37
65.79 thromboxane Az synthesis and expression of procoagulant activity,
resorption, prostaglandin-induced increase in neonatal mouse 65.133
calvaria, 64.117 vascular complications, thromboxane/prostacyclin ratio and,
Bone marrow cells, expression of adipogenesis markers, 65.216 65.191
©2001 Harcourt Publishers Ltd Prostaglandins, Leukotrienes and Essential Fatty Acids (2001) 65(5&6), 307-311
308 Subject index
Diet dietary, modulation of urothelial proliferation and apoptosis,
polyunsaturated fatty acids 64.151
effect on insulin sensitivity and lipid metabolism in OLETF rats, effect of fish-oil supplements in pregnancy on_ neonatal
64.181 long-chain polyunsaturated fatty acid status, 65.51
modulation of urothelial proliferation and apoptosis, 64.151 effect on insulin sensitivity and lipid metabolism in OLETF rats,
restricted, opioid effects on uterine glucose and eicosanoid 64.181
metabolism, 65.117 glucose-insulin-potassium regimen and, effect in lupus and
Docosahexaenoic acid (DHA) other inflammatory conditions, 65.109
effects of eicosapentaenoic acid/docosahexanoic acid in glomeru- polyunsaturated long-chain, biochemical effects of supplementa-
lar disorders, 65.197 tion in hyperphenylalaninemia, 64.111
effects on rat liver and reproductive tissue, 65.23 role of a novel derivative pentacyclic triterpene and 3 fatty acid
prevention of activation of cyclin-dependent kinases ad S-phase (Lupeol-EPA) in adjuvant induced arthritis, 64.81
entry by serum stimulation in HT-29 cells, 64.67 uptake and metabolic conversion in Hep2 larynx tumor cells,
supplementation in essential fatty acid deficiency, effects on 65.295
cellular fatty acid acyl desaturation, 64.11 Fatty acyl CoA esters, effects on prostaglandin and arachidonoyl-CoA
Doxorubin-induced damage in cardiomyocytes, counteracting role of formed from arachidonic acid in kidney medulla, 64.61
-linolenic acid, 64.139 Fish oil
Dyslexia, platelet activating factor and, 64.173 effect on eicosanoids of low-dose aspirin combined with fish oil,
64.291
effect on lipid peroxidation of short-term dietary administration of
marginal levels, 64.265
effect of three low-dose supplements in pregnancy on neonatal
long-chain polyunsaturated fatty acid status, 65.51
Eicosanoids
Flavonoids, differential effects on epidermal cytosolic phospholipase
antidepressants and, cancer prevention and treatment, 65.233
effect of low-dose aspirin combined with fish oil, 64.291 A2, 65.281
from human saphenous vein endothelial cells, profile and effect of
dietary fatty acids, 65.15
G
metabolism in restricted diet rats, effects of opioids, 65.117
see also specific eicosanoids
Eicosapentaenoic acid (EPA) Gamma-linolenic acid, role in counteracting doxorubicin-induced
attenuation of oxalate-induced nephrotoxicity by eicosapentaeno- damage in cardiomyocytes, 64.139
ate-lipoate derivative, 65.265 Garlic-induced hypotension, possible mechanism, 64.5
role of Lupeol-EPA in adjuvant induced arthritis in rats, 64.81 Glomerular disorders, effect of corticosteroids and eicosapentaenoic
Eicosapentaenoic acid/docosahexanoic acid, effects in glomerular acid/docosahexaenoic acid, 65.197
disorders, 65.197 Glucose metabolism in restricted diet rats, effects of opioids, 65.117
Electrical stimulation, effect on prostaglandin production in rat vas Glucose-insulin-potassium regimen combined with polyunsaturated
fatty acids, lupus and other inflammatory conditions, 65.109
deferens, 65.9
Endothelins Glutathione levels after skeletal muscle ischemia-reperfusion, effects
involvement in respiratory centre activity, 65.157 of nitric oxide, 65.179
relationship with nitric oxide in intestinal ischemia/reperfusion Growth factors, vascular endothelial, prostaglandin E modulation of
production in macrophages, 65.123
injury, 64.253
role in prevention of cyclosporine-induced nephrotoxicity, 64.231
Enzyme immunoassay (EIA), measurement of urinary PGE, in | H
infants, 64.317
Essential fatty acids see under Fatty acids
Exercise: response of muscle interstitial prostaglandin E2, prostacy- 15-Hydroxyprostaglandin dehydrogenase mRNA expression
clin and thromboxane Az during incremental dynamic exercise HL60 cells differentiated by PMA, effect of indomethacin, 64.87
determined by in vivo microdialysis, 64.259 murine uterine and gestational tissues in late pregnancy, 64.247
Hyperphenylalaninemia, biochemical effects of supplemented long-
chain polyunsaturated fatty acids, 64.111
Hypertension
CsA-induced, nitric oxide in: role of f-adrenoreceptor antagonist
and thromboxane A>, 65.259
Fatty acids
dietary polyunsaturated fatty acid and modification of vascular
brain and hippocampus composition, aged-relative cognitive
dysfunction, 65.91
deficit rats, 64.189 pulmonary, effects of beraprost, 64.197
composition, effect of dietary gamma-linolenic acid, 65.205 thromboxane Bp, prostaglandin Ez and hypertension in rat 2-
in composition of milk lipids of Nepalese women, 65.147
kidney 1-clip model, 64.5
dietary, effect on eicosanoids produced by saphenous vein
Hypotension, garlic-induced, possible mechanism, 64.5
endothelial cells, 65.15
essential
deficiency and supplementation with DHA; 22: 6n-3), effects on
cellular fatty acid acyl desaturation, 64.11 I
as mediators of statins, 65.37
modulation of intestinal vitamin D receptor availability and Ibuprofen, attenuation of early lung injury in endotoxemic, neutro-
calcium ATPase activity, 64.147 penic rats, 65.59
vegetarians and non-vegetarians, 64.53 Immune function, effect of dietary gamma-linolenic acid, 65.205
plasma levels in autistic children, 65.1 Immunohistochemical localization of prostacyclin receptor (IP) in
polyunsaturated bone, 65.79
dietary, effect on airway contractility, 64.281 Indomethacin
dietary, modification of vascular dysfunction in hypertension, effect on 15-PGDH mRNA expression in HL60 cells differentiated
65.91 by PMA, 64.87
Prostaglandins, Leukotrienes and Essential Fatty Acids (2001) 65(5&6), 307-311 ©2001 Harcourt Publishers Ltd
Subject Index 309
effects on prostaglandin production by placenta, 64.23 Lupus erythematosus, effect of glucose-insulin-potassium regimen
and release of arachidonic acid from rat liver cells, 65.31 combined with polyunsaturated fatty acids, 65.109
Inflammatory disorders, effect of glucose-insulin-potassium regimen
combined with polyunsaturated fatty acids, 65.109
Insulin M
glucose-insulin-potassium regimen combined with polyunsatu-
rated fatty acids, effect in lupus and other inflammatory Macrophage activation, differential mRNA expression of prostaglan-
conditions, 65.109 din receptor subtypes, 65.287
sensitivity to, effect of dietary polyunsaturated fatty acid, 64.181 Malondialdehyde, effects of nitric oxide after skeletal muscle
Ischemia, lower limb, effect of revascularisation on leukotriene E4 ischemia-reperfusion, 65.179
production, 64.289 Microdialysis in vivo technique, determination of responses during
Ischemia-reperfusion injury incremental dynamic exercise, 64.259
intestinal, nitric oxide and endothelin relationship in, 64.253 Milk, human
skeletal muscle, effects of nitric oxide following, 65.179 fat composition and breastfeeding duration, effect on develop-
Isoprostanes mental indices at 1 year, 64.105
6-oxo-PGF,, and 8-epi-PGF>, in arterial wall layers, 64.167 fatty acid composition of milk lipids of Nepalese women, 65.147
8-iso-PGF>, excretion rate, 65.99 mRNA
increase of 8-epi-PGF>, after restarting smoking, 64.307 differential expression, prostaglandin receptor subtypes in macro-
transcardiac 8-iso-prostaglandin F2, generation from acute myo- phage activation, 65.287
cardial infarction heart: marker for oxidant stress, 64.161 expression, cytosolic phospholipase Az and 15-hydroxyprostaglan-
din dehydrogenase in uterine and gestational tissues, 247
Muscle, skeletal, effects of nitric oxide after ischemia-reperfusion,
| K
65.179
Kinases, cyclin-dependent, effects of docosahexaenoic acid, 64.67 | N
| 1 |
Natriuresis, volume-induced, in healthy women, 64.95
Nephrotoxicity
Larynx tumor cells Hep2, uptake and metabolic conversion of fatty cyclosporine-induced, preventive role of prostanoids and endothe-
acids, 65.295 lins, 64.231
Leukotriene E4 (LTE,) oxalate-induced, attenuation by eicosapentaenoate-lipoate deriva-
production, effect of revascularisation of ischaemic lower limb, tive, 65.265
64.289 Nitric oxide
urinary, rheumatoid arthritis, 65.301 cyclopsorine A-induced hypertension, role of 6-adrenoreceptor
Linoleic acids antagonist and thromboxane A2, 65.259
conjugated, effects on rat liver and reproductive tissue, 65.23 effect on PGE2 generation in diabetic embryo, 64.127
dose-dependent effects of dietary gammaz-linolenic acid on fatty effects after skeletal muscle ischemia-reperfusion, 65.179
acid composition and immune parameters, 65.205 relationship with endothelins in intestinal ischemia/reperfusion
Linolenic acid, gamma, role in counteracting doxorubicin-induced injury, 64.253
damage in cardiomyocytes, 64.139 in streptozotocin-pancreatic damage, 64.311
Lipid body formation in leukocytes, arachidonyl trifluoromethyl Non-steroidal anti-inflammatory drugs (NSAIDs), evaluation on
ketone and, 64.227 purifed ovine enzymes and human whole blood, 64.211
Lipid metabolism, effect of dietary polyunsaturated fatty acid, 64.181 NS-398, effects on prostaglandin production by placenta, 64.23
Lipid peroxidation
effects of short-term dietary administration of marginal levels of
oO
vitamin B, and fish oil, 64.265
microsomes and mitochondria from different rat tissues: effect of
retinyl palmitate, 64.75 Opioids, effects on uterine glucose and eicosanoid metabolism in
product levels in bovine retained and not retained placenta, 64.33 restricted diet rats, 65.117
Lipids Opunita robusta ingestion, effect on oxidation injury, 65.45
dietary, airway contractility and, 64.281 Osteoblasts
effect of arachidonic acid-rich oil in ethanol-treated rats, 64.273 characterization of prostaglandin receptors in, 64.203
peroxidation sphingosine-1-phosphate effects on PKC isoform expression,
lung surfactant, inhibition by surfactant protein A, 65.185 65.139
in pancreatic cancer, influence of antioxidative vitamins, 65.165 Oxalate-induced nephrotoxicity, attenuation by eicosapentaenoate-
Lipoic acid: attenuation of oxalate-induced nephrotoxicity by lipoate derivative, 65.265
eicosapentaenoate-lipoate derivative, 65.265 Oxidant stress, vegetarians and non-vegetarians, 64.53
Lipopolysaccharide, gestational age-dependent effects on prostaglan- Oxidation injury
din production, 64.135 effect of opunita robusta ingestion, 65.45
15-Lipoxygenase-1 activity and localization in colorectal carcinoma smoking and, 64.307
Caco-2 cells, 64.217 Oxygen, intravenous, effects on prostacyclin and thromboxane
Liver formation in peripheral occlusive arterial disease, 65.211
effects of conjugated linoleic acids and docosahexaenoic acid,
65.23
stimulated release of arachidonic acid by celecoxib and indo- P
methacin, 65.31
Lower limb ischaemia, effect of revascularisation on leukotriene E4 Pancreas, streptozotocin-induced damage, inducible isoforms of COX
production, 64.289 and NOS in, 64.311
Lung injury, ibuprofen attenuation of early injury, 65.59 Pancreatic cancer, influence of vitamins A, C and E on lipid
Lupeol-EPA, role in relation to lysosomal enzymes, glycoproteins and peroxidation, 65.165
collagen in adjuvant induced arthritis, 64.81 Paraoxonase activity, aging and, 65.241
© 2001 Harcourt Publishers Ltd Prostaglandins, Leukotrienes and Essential Fatty Acids (2001) 65(5&6), 307-311
310 Subject Index
Pentacyclic triterpene, role of a novel derivative pentacyclic triter- immunohistochemical localization of receptor (IP) in bone, 65.79
pene and «3 fatty acid (Lupeol-EPA) in adjuvant induced arthritis, muscle interstitial, response in dynamic exercise determined by in
64.81 vivo microdialysis, 64.259
Peroxidation, lipids see Lipids, peroxidation renal metabolism in volume-induced natriuresis, 64.95
Peroxisome proliferator-activated receptor agonists, stimulation of TXA2/prostacyclin ratio and diabetic vascular complications,
arachidonic acid release, 65.229 65.191
Peroxisome proliferator-activated receptor-y expression in malignant Prostaglandins
and normal cell lines, 241 biosynthesis in dispersed choriodecidual cells in culture, 65.247
Phospholipase Az effect of bradykinin and electrical stimulation on production in rat
cytosolic, mRNA expression in murine uterine and gestational vas deferens, 65.9
tissues in late pregnancy, 64.247 effects of fatty acyl CoA esters on formation in kidney medulla,
epidermal cytosolic, differential effects of flavonoids, 65.281 64.61
Phytosterols, dietary, effect on vascular smooth muscle cells, 64.323 induction of bone resorption in neonatal mouse calvaria, 64.117
Placenta production by murine decidual caps, gestational age-dependent
bovine retained/not retained, lipid peroxidation product levels, effects of lipopolysaccharide, 64.135
64.33 production by placenta: effects of indomethacin, NS-398 and
prostaglandin production, effects of indomethacin, NS-398 and protein synthesis inhibitors, 64.23
protein synthesis inhibitors, 64.23 receptors, characterization in osteoblasts, 64.203
Platelet activating factor, dyslexia and, 64.173 see also Isoprostanes
Platelet-activating factor acetylhydrolase activity, aging and, 65.241 Prostanoids
Platelet function, activity of movel thromboxane Aj2 receptor pharmacology of IP prostanoid receptors in NCB-20 cells, 65.253
antagonist and thromboxane synthase inhibitor, 65.67 physiological role in volume-induced natriuresis, 64.95
Polyunsaturated fatty acids see under Fatty acids role in prevention of cyclosporine-induced nephrotoxicity, 64.231
Potassium: glucose-insulin-potassium regimen combined with poly- Protein synthesis inhibitors, effects on prostaglandin production by
unsaturated fatty acids, effect in lupus and other inflammatory placenta, 64.23
conditions, 65.109
Pranlukast hydrate, effect on acetaldehyde-induced bronchocon-
R
striction in asthmatics, 65.41
Pregnancy Radioimmunoassay combined with solid-phase extraction, determi-
cytosolic phospholipase Az and 15-hydroxyprostaglandin dehy-
nation of 9x,118-PGF> in urine, 65.271
drogenase mRNA expression in murine uterine and gestational Renal insufficiency, effect of PGI, analogue on progression rate of
tissues in late pregnancy, 64.247
renal dysfunction, 65.223
effects of conjugated linoleic acids and docosahexaenoic acid on
Reproductive tissue, effects of conjugated linoleic acids and
reproductive tissue, 65.23
docosahexaenoic acid, 65.23
fish-oil supplements, effect on neonatal long-chain polyunsatu-
Respiratory system mechanics, endothelin and, 65.157
rated fatty acid status, 65.51
Retinoic acid receptor agonists, stimulation of arachidonic acid
gestational age-dependent effects of lipopolysaccharide on pros-
release, 65.229
taglandin production, 64.135
Retinyl palmitate, effect on lipid peroxidation of microsomes and
Prickly pear see Opunita robusta
mitochondria from different rat tissues, 64.75
Procoagulant activity, expression in diabetes mellitus, 65.133 Rheumatoid arthritis
Propanolol, prevention of cyclopsorine A-induced hypertension,
analysis of urinary prostacyclin and thromboxane/prostacyclin
65.259
ratio, 65.85
Prostacyclin see Prostaglandin I,
urinary 11-dehydro TXB2 and LTE, excretion, 65.301
Prostaglandin Az (PGA2): tyrosine kinase-phosphorylated protein in
PGA>-treated cells, 65.173
Prostaglandin E2 (PGE2) Ss
concentrations in naturally occuring canine cancer, 64.1
effects of nitric oxide on PGE;-like activity after skeletal muscle Saphenous vein endothelial cells, profile of eicosanoids produced and
ischemia-reperfusion, 65.179 effect of dietary fatty acids, 65.15
modulation of generation in diabetic embryo, 64.127
Shock, endotoxic, bosentan and, 65.103
modulation of vascular endothelial growth factor production in Smoking, effect of restarting on isoprostane 8-epi-PGF2,, 64.307
macrophages, 65.123 Smooth muscles, activity of novel thromboxane A; receptor antago-
muscle interstitial, response in dynamic exercise determined by in nist and thromboxane synthase inhibitor, 65.67
vivo microdialysis, 64.259 Sphingosine-1-phosphate (SIP) effects on PKC isoform expression in
receptors, differential mRNA expression in macrophage activation,
osteoblasts, 65.139
65.287
Statins, essential fatty acids as mediators of action, 65.37
thromboxane-B2, prostaglandin E2 and hypertension in rat Stone formation, inhibition by eicosapentaenoate-lipoate derivative,
2-kidney 1-clip model, 64.5
65.265
urinary concentrations measured by new EIA method in infants, Streptozotocin-induced pancreatic damage, inducible isoforms of
64.317
COX and NOS in, 64.311
Prostaglandin F2 (PGF2): determination of 9«,118-PGF, in urine by Superoxide dismutase, effect on PGE2 generation in diabetic embryo,
combined solid-phase extraction and radioimmunoassay, 65.271
64.127
Prostaglandin F2, (PGF>2,) Surfactant: surfactant protein A inhibition of lipid peroxidation of
angiotensin-induced release via L-type calcium channels, 65.73
lung surfactant, 65.185
metabolite (15-keto-dihydro-PGF>2,) excretion rate, 65.99
Prostaglandin Iz (PGI2; prostacyclin)
analysis of urinary prostacyclin and thromboxane/prostacyclin L
ratio in rheumatoid arthritis, 65.85
effect of PGI, analogue on progression rate of renal dysfunction,
65.223 Thromboxane
formation in peripheral occlusive arterial disease, effects of formation in peripheral occlusive arterial disease, effects of
intravenous oxygen, 65.211 intravenous oxygen, 65.211
Prostaglandins, Leukotrienes and Essential Fatty Acids (2001) 65(5&6), 307-311 ©2001 Harcourt Publishers Ltd
Subject index 311
renal metabolism in volume-induced natriuresis, 64.95 | Vv
Thromboxane A> (TXAz2)
cyclopsorine A-induced hypertension, 65.259
Vascular dysfunction, modulation in hypertension, dietary polyunsa-
muscle interstitial, response in dynamic exercise determined by
turated fatty acid and, 65.91
in vivo microdialysis, 64.259
Vascular endothelial growth factor, prostaglandin E2 modulation of
synthesis in diabetes mellitus, 65.133
production in macrophages, 65.123
TXA2/prostacyclin ratio and diabetic vascular complications, Vascular smooth muscle cells, effect of plant sterols, 64.323
65.191 Vegetarians: oxidant stress, anti-oxidants and essential fatty acids in
Thromboxane Az receptor antagonist, novel, activity on platelet
vegetarians and non-vegetarians, 64.53
function and isolated smooth muscles, 65.67
Vitamin B,, effect on lipid peroxidation of short-term dietary
Thromboxane Bz (TXB)
administration of marginal levels, 64.265
thromboxane-B2, prostaglandin Ez and hypertension in rat 2-
Vitamin D receptor availability modulation due to EFA supplementa-
kidney 1-clip model, 64.5
tion, effect on calcium retention, 64.147
urinary 11-dehydro TXB2 in rheumatoid arthritis, 65.301 Vitamins: influence of vitamins A, C and E on lipid peroxidation in
Tyrosine kinase-phosphorylated protein in arachidonic acid- and
pancreatic cancer, 65.165
prostaglandin A>-treated cells, 65.173
©2001 Harcourt Publishers Ltd Prostaglandins, Leukotrienes and Essential Fatty Acids (2001) 65(5&6), 307-311
Prostaglandins, Leukotrienes and Essential Fatty Acids (2001) 65(5&6), 312-315
© 2001 Harcourt Publishers Ltd
Author Index
| A Chuang, L-T., 65.147
Ciminaghi, B., 65.103, 157
Clement, M.G., 65.103, 157
Abeywardena, M.Y., 64.281; 65.91
Coffman, K., 64.1
Abo, M., 65.41
Cornicelli, J.A., 64.217
Agnoli, D.C., 64.95
Cottereaux, C., 64.117
Agostoni, C., 64.105, 111
Cremonezzi, D.C., 64.151
Aitken, H., 64.23
Aktan, A.O., 64.253 Crider, J.Y., 65.253
Al-Qattan, K.K., 64.5 Cuzzolin, L., 64.317
Alaniz, MJ.T. de, 65.295
Albertini, M., 65.103, 157 |
Albino, L., 65.295
Ali, M., 64.5 Dagli, T-E., 64.253
Allen, K.G.D., 65.23 Daphtary, K.M., 65.59
Alnageeb, M.A., 64.5 Darlametsos, LE., 64.231
Ampatzidis, G., 64.259 Das, U.N., 64.37, 53; 65.37, 109, 197
Andrés, C., 65.1 David, J.-L., 64.211
Angelopoulou, N., 64.259
de Alaniz, MJ.T., 65.295
Awad, A.B., 64.323 de Bravo, M.G., 65.295
De Brum-Fernandes, AJ., 65.79
de Leval, X., 64.211
Delarge, J., 64.211; 65.67
DeNicola, D.B., 64.1
Babiil, A., 65.179 Devel, P., 64.211
Barthélémy, C., 65.1
Dick, J.R., 64.11
Basu, S., 65.99 Dijs, F.P.L. van der, 65.51
Baudoin, C., 64.87 Dogné, J.-M., 64.211
Bergami, R., 64.265 Dogné, J.M., 65.67
Beusekom, C.M. van, 65.51 Du Toit, PJ., 65.173
Bhatt, S.K., 65.147 Dumais, R., 64.203
Biagi, P.L., 64.139 Durakbasa, C.U., 64.253
Bianchi, P.C., 65.173 Durand, G., 65.1
Bkaily, G., 64.203 Dziak, R., 65.139
Blanco, O., 65.185
Blanqué, R., 64.117
Bonvissuto, M., 64.111
Bordoni, A., 64.139
Borgatti, R., 64.95 Efthimiou, Y., 65.45
Bozza, P.T., 64.227 Eling, T.E., 64.217
Bravo, M.G. de, 65.295 Endo, M., 65.223
Brum-Fernandes, AJ. de, 64.203 Engstrom, K., 64.291
Bruzzese, M.G., 64.111 Erickson, K.L., 65.123, 287
Budinsky, A., 65.45 Eynard, A.R., 64.151
Budinsky, A.C., 64.307
Fanos, V., 64.317
Fink, C.S., 64.323
Cabrini, L., 64.265
Fortier, I., 65.79
Cacciari, M., 64.95
Frenkian, M., 64.87
Campos, MLL., 65.117
Frolich, J.C., 65.211
Capello, JJ., 65.51
Fujimoto, Y., 64.61
Capoblanco, E., 64.127
Fujimura, M., 65.41
Carloni, A., 64.265
Fujita, T., 64.61; 65.223
Casalino-Matsuda, S.M., 65.117 Fuke, Y., 65.223
Catala, A., 64.75; 65.185
Fukunaga, M, 64.161
Celuch, S.M., 65.9
Chalon, S., 65.1
Che, Z.-Y., 64.67
Chehne, F., 64.307
Chiba, S., 65.301 Galli, C., 64.105
Christoulas, K., 64.259 Garcia Palacios, V., 65.215
Prostaglandins, Leukotrienes and Essential Fatty Acids (2001) 65(5&6), 312-315 ©2001 Harcourt Publishers Ltd
Author index
Gardner, C.R., 64.117 Kilian, M., 65.165
Gimeno, M.A.F., 64.127; 65.115 Kim, H.P., 65.281
Giovannini, M., 64.105, 111 Kita, T., 65.41
Glew, R.H., 65.147 Kitao, A., 64.61
Glibetic, M., 65.59 Klis, FR.M. van der, 65.51
Glickman, N.W., 64.1 Knapp, D.W., 64.1
Goldraij, A., 65.117 Komatsu, K., 65.223
Gonzalez, E., 64.311 Konieczkowski, M., 65.133
Gonzalez, E.T., 64.127 Koslo, J.L., 65.23
Guilloteau, D., 65.1 Kreutzer, FJ., 65.211
Gupta, D.K., 64.135, 247
Krishna Mohan, L., 65.197
Guski, H., 65.165 Kritz, H., 64.167
Gutzki, F-M., 65.211 Kruger, M.C., 64.147
Kubota, M., 64.181
Kurumatani, H., 64.197
Kuukasjarvi, P., 64.289
Haag, M., 64.147
Haché, R., 64.203
Haklar, G., 64.253
Hansen, R.A., 65.23
Lafortuna, C.L., 65.157
Harris, M.A., 65.23
Lammardo, A.M., 64.105
Hashimoto, T., 65.41
Lampasso, J.D., 65.139
Hashimura, K., 64.161
Landman, H., 65.51
Hasuda, K., 64.181
Latha, R.M., 64.81
Hayek, M.G., 64.1
Lee, S-H., 65.287
Head, RJ., 64.281; 65.91
Lejeune, B., 65.1
Heidemann, S.M., 65.59
Lenin, M., 64.81; 65.265
Helmersson, J., 65.99
Lenzi, P., 64.95
Henrotin, Y., 64.211
Leonard, F., 64.147
Hidaka, M., 65.223
Leval, X. de, 64.211
Hishinuma, T., 65.85, 191, 301
Levine, L., 65.31, 229
Hrelia, S., 64.139
Lieb, J., 65.233
Hsi, L.C., 64.217
Lim, D., 65.287
Huang, Y-S., 65.147
Linares, J.A., 65.117
Hubbard, N.E., 65.123, 287
Lora, M., 65.79
Lottering, M-L., 65.173
Lupattelli, G., 64.307
Inoue, H., 65.85, 301 |
Ishii, K., 64.181
Istfan, N.W., 64.67
Magnussen, M.A., 65.147
Mandroukas, K., 64.259
Mangiarotti, P., 64.317
Manjari, V., 64.53
Jablonskis, L.T., 64.281 Maranesi, M., 64.265
Jacobi, C.A., 65.165
Marangoni, F., 64.105
Jagt, DJ. vander, 65.147
Marchetti, M., 64.265
Jagt, T.A. vander, 65.147 Margarone, J. III, 65.139
Jawerbaum, A., 64.127, 311
Marinelli, M., 64.95
Joubert, A.M., 65.173 Martineau, J., 65.1
Joubert, F., 65.173
Marvin, K.W., 64.247; 65.247
Jullienne, A., 64.87
Masereel, B., 65.67
Matsumoto, F., 65.85, 301
|
Matsushita, T., 64.197
Matsu-ura, Y., 64.161
Kaku, S., 65.205 Mazzola, S., 65.103, 157
Kamer, A., 65.139 Michaux, C., 64.211; 65.67
Kamio, Y., 65.41 Milochevitch, C., 65.241
Kamitani, H., 64.217 Mimouni, V., 64.189
Kaneyuki, T., 64.273 Mitchell, M.D., 64.135, 247; 65.247
Kankofer, M., 64.33 Mitomo, T., 65.85, 301
Karamazouzis, I., 64.259 Mizugaki, M., 65.85, 191, 301
Karamazouzis, M., 64.259 Mohammed, S.I., 64.1
Katayama, N., 65.41 Morita, I., 65.215
Kato, Y., 64.161 Mucha, R., 65.271
Katoh, Y., 64.61 Mukutmoni, M., 65.123
Keelan, J.A., 64.135, 247 Miiller, J.M., 65.165
Khalil, A., 65.241 Murota, S., 65.215
Khan, I., 64.5 Musket, F.AJ., 65.51
Kijima, Y., 64.161 Myou, S., 65.41
©2001 Harcourt Publishers Ltd Prostaglandins, Leukotrienes and Essential Fatty Acids (2001) 65(5&6), 312-315
314 Author Index
Samadfan, R., 65.79
Sarrazin, P., 64.203
Sasagawa, T., 64.181, 273
Nagaraj, M., 65.265
Sato, T.A., 64.135, 247
Nakamura, H., 65.85, 301
Satomura, A., 65.223
Nakao, S., 65.41
Sawai, T., 65.85, 301
Neven, P., 64.211
Sayan, H., 65.179
Nicolaou, A., 65.15
Scaglioni, S., 64.111
Nishitsuji, M., 65.41
Schanz, N., 65.259
Nomura, S., 65.41
Schimke, I., 65.165
Nonaka, M., 65.205
Schlittler, D., 64.1
Nowak, V., 65.211
Seegers, J.C., 65.173
Nwankwo, J.O., 64.241
= Segond, N., 64.87
Sharif, N.A., 65.253
Silva, R.A., 64.151
Sinner, D., 64.127; 65.115
Oguogho, A., 64.167, 307; 65.45 Sinzinger, H., 64.167, 299, 307; 65.45
Ohi, H., 65.223 Skrinska, V.A., 65.133
Ohkura, K., 65.205 Smith, AJ., 64.323
Ohsawa, I., 65.223 Stahlknecht, P., 65.165
Ohta, Y., 64.273 Stamatopoulos, Y., 65.45
Okita, M., 64.181, 273 Stein, J.F., 64.173
Oriji, G.K., 65.73, 259 Stichentoth, D.O., 65.211
Orita, Y., 64.161 Stipo, L., 64.95
Ota, Y., 64.181 Sugano, M., 65.205
Ozel, $K., 64.253 Suresh, Y., 64.37, 53
| Suzuki, K., 64.273; 65.191
Suzuki, N., 65.301
Palacios, A., 64.75
Palumbo, B., 64.307
Panzer, A., 65.173 Tachibana, H., 65.205
Parkin, S.M., 65.15 Takabatake, M., 65.301
Patry, C., 64.203; 65.79 Tamura, M., 64.197
Peralta, C., 65.115 Taylor, K.E., 64.173
Peredo, H.A., 65.9 Thiagarajan, A., 65.265
Pham, H.T., 65.281 Thomas, J.B., 65.23
Pidoux, E., 64.87 Tocher, D.R., 64.11
Piergiacomi, V.A., 64.75 Tolomelli, B., 64.265
Pilar Diaz, M.del, 64.151 Tsikas, D., 65.211
Pirotte, B., 64.211 Tsukamoto, H., 65.191, 301
Poisson, J.-P., 64.189
Polo, M.P., 65.295 |
Porsolt, R., 64.189
Poyser, N.L., 64.23
Pustovrh, C., 64.127; 65.115 Ueda, T., 64.161
Ugurlu, B., 65.179
Ulmann, L., 64.189
Urquhart, P., 65.15
Rasool, M., 64.81 [
Ravi Raju, T., 65.197
Reiter, R., 64.299
Resch, U., 64.299 Valentich, M.A., 64.151
Richardson, AJ., 64.173 Vamvakoudis, E., 64.259
Ridders, J., 65.165 Van Beusekom, C.M., 65.51
Riutta, A., 64.289; 65.271 Van der Dijs, F.P.L., 65.51
Riva, E., 64.105, 111 Vancassel, S., 65.1
Robbins, M.E.C., 64.241 Van der Klis, F.R.M., 65.51
Rocha, F.A.C., 64.203 Vander Jagt, DJ., 65.147
Rolin, S., 65.67 Vander Jagt, T.A., 65.147
Rosell6-Catafau, J., 64.311 Varalakshmi, P., 64.81; 65.265
Rossi, P., 64.289 Varonos, D.D., 64.231
Roux, S., 64.189 Vela, J., 65.115
Velzing-Aarts, F.V., 65.51
Vidsudhiphan, P., 65.23
Sailaja Devi, M.M., 64.53 |
Sakuma, S., 64.61
Saldeen, T., 64.291 Wagner, O., 64.167
Salenius, J.P., 64.289 Wallin, R., 64.291
Prostaglandins, Leukotrienes and Essential Fatty Acids (2001) 65(5&6), 312-315 ©2001 Harcourt Publishers Ltd
Author index 315
Waters, DJ., 64.1
Watkins, B.A., 65.23
Weller, PF, 64.227 Yamada, K., 65.205
Wenger, F.A., 65.165 Yasuda T. 64.161
White, V., 64.127; 65.115 Tare aaa
Wolfram, R., 65.45 hess Pap eso d
Yunoki, S., 65.205
Xaus, C., 65.115
Xu, S.X., 65.253 Ziboh, V.A., 65.281
©2001 Harcourt Publishers Ltd Prostaglandins, Leukotrienes and Essential Fatty Acids (2001) 65(5&6), 312-315